Urinary Phthalate Biomarker Concentrations and Postmenopausal Breast Cancer Risk.
Urinary Phthalate Biomarker Concentrations and Postmenopausal Breast Cancer Risk.
复制标题
尿邻苯二甲酸盐生物标志物浓度和绝经后乳腺癌风险。
DOI：
10.1093/jnci/djz002
复制
发表时间：
2019
期刊：
影响因子：
--
通讯作者：
Cheng,Ti
中科院分区：
文献类型：
--
作者：
Reeves,KatherineW;DíazSantana,Mary;Manson,JoAnnE;Hankinson,SusanE;Zoeller,RThomas;Bigelow,Carol;Sturgeon,SusanR;Spiegelman,Donna;Tinker,Lesley;Luo,Juhua;Chen,Bertha;Meliker,Jaymie;Bonner,MatthewR;Cote,MicheleL;Cheng,Ti
背景越来越多的实验室和动物模型证据支持一些邻苯二甲酸酯的潜在致癌作用，邻苯二甲酸酯是在各种消费品中用作增塑剂的化学品，包括化妆品、药物和乙烯基地板。然而，前瞻性数据邻苯二甲酸酯是否与人类乳腺癌的风险是lacking.MethodsWe进行了嵌套的病例对照研究内的妇女健康倡议（WHI）的前瞻性队列（n = 419侵入性病例受试者和838对照组）。对照组受试者与病例组受试者在年龄、入组日期、随访时间和WHI研究组方面按2：1匹配。我们在一到三年内对每位参与者的两到三份尿样中的13种邻苯二甲酸酯代谢物和肌酐进行了定量。多变量条件logistic回归分析用于估计与每种邻苯二甲酸酯生物标志物相关的乳腺癌风险的比值比（OR）和95%置信区间（CI），随访时间长达19年。（例如，邻苯二甲酸二乙基己酯的第4和第1四分位数，OR = 1.03，95% CI = 0.91 - 1.17）。结果一般是相似的分析仅限于疾病亚型，绝经后激素治疗的非用户，分层的身体质量指数，或在三，五，或ten years.ConclusionsIn第一次前瞻性分析邻苯二甲酸酯和绝经后乳腺癌，邻苯二甲酸酯的生物标志物浓度并没有导致发展为浸润性乳腺癌的风险增加。
BackgroundGrowing laboratory and animal model evidence supports the potentially carcinogenic effects of some phthalates, chemicals used as plasticizers in a wide variety of consumer products, including cosmetics, medications, and vinyl flooring. However, prospective data on whether phthalates are associated with human breast cancer risk are lacking.MethodsWe conducted a nested case-control study within the Women’s Health Initiative (WHI) prospective cohort (n = 419 invasive case subjects and 838 control subjects). Control subjects were matched 2:1 to case subjects on age, enrollment date, follow-up time, and WHI study group. We quantified 13 phthalate metabolites and creatinine in two or three urine samples per participant over one to three years. Multivariable conditional logistic regression analysis was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for breast cancer risk associated with each phthalate biomarker up to 19 years of follow-up.ResultsOverall, we did not observe statistically significant positive associations between phthalate biomarkers and breast cancer risk in multivariable analyses (eg, 4th vs 1st quartile of diethylhexyl phthalate, OR = 1.03, 95% CI = 0.91 to 1.17). Results were generally similar in analyses restricted to disease subtypes, to nonusers of postmenopausal hormone therapy, stratified by body mass index, or to case subjects diagnosed within three, five, or ten years.ConclusionsIn the first prospective analysis of phthalates and postmenopausal breast cancer, phthalate biomarker concentrations did not result in an increased risk of developing invasive breast cancer.